Amgen RPE
Quel est le RPE de Amgen?
Le RPE de Amgen, Inc. est $60.018k
Quelle est la définition de RPE?
Le revenu par employé (RPE) est le revenu divisé par le nombre d'employés d'une organisation.
RPE des entreprises dans Health Care secteur sur XETRA par rapport à Amgen
Que fait Amgen?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Entreprises avec rpe similaire à Amgen
- KB Recycling Industries Ltd a RPE de $59.850k
- Theranexus SA a RPE de €59.889k
- Avivagen a RPE de CAD$59.923k
- Sporting Clube de Braga - Futebol, SAD a RPE de €59.933k
- EXMAR NV a RPE de $59.960k
- Idsud S.A a RPE de €60.000k
- Amgen a RPE de $60.018k
- Mitchells & Butlers Plc a RPE de £60.364k
- Alveen S.A a RPE de €60.369k
- Victoria Oil & Gas Plc a RPE de $60.438k
- Almonty Industries a RPE de CAD$60.495k
- Majesco a RPE de $60.524k
- Majesco a RPE de $60.524k